Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2026-03-25 Regulatory Filings
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Pharma Equity Group A/S - Annual Report 2025
Regulatory Filings
2026-03-25 Danish
Pharma Equity Group A/S - Annual Report 2025
Report Publication Announcement Classification · 1% confidence The document is an announcement from Pharma Equity Group A/S regarding their 2025 Annual Report ('Årsrapport 2025'). It provides a summary of key financial highlights, operational updates, and future outlooks. While it contains substantive financial data (tables and performance metrics), it is structured as a press release/announcement (Announcement no. 3) rather than the full, audited annual report document itself. According to the 'Menu vs Meal' rule, this is a summary announcement of the report, which falls under the Report Publication Announcement (RPA) category. FY 2025
2026-03-25 Danish
Pharma Equity Group A/S - Annual Report 2025
Report Publication Announcement Classification · 1% confidence The document is a company announcement summarizing and approving the 2025 annual report, providing key highlights, summary financial tables, post-period events, and strategy outlook, and directing readers via links to the full PDF annual report. It does not contain the full audited statements and notes itself but attaches or links to them. Per the "menu vs. meal" rule, this is a Report Publication Announcement rather than the full Annual Report.
2026-03-25 Danish
Pharma Equity Group A/S - Annual Report 2025
Regulatory Filings
2026-03-25 Danish
Pharma Equity Group A/S - Annual Report 2025
Earnings Release Classification · 1% confidence The document is a formal announcement by the Board that the Annual Report for fiscal year 2025 has been reviewed and approved, and it provides key financial and operational highlights (profit/loss, balance sheet figures, post-year events, guidance, etc.). It does not contain the full annual report text, nor is it a short notice pointing to attachment or link—it is clearly the initial public release of the year-end results. Therefore it aligns with an Earnings Release (ER) rather than the full 10-K or a mere publication notice. FY 2025
2026-03-25 English
Pharma Equity Group A/S - Annual Report 2025
Report Publication Announcement Classification · 1% confidence The document is clearly titled “Pharma Equity Group A/S – Annual Report 2025” but is structured as a press‐release summary (announcement no. 3) with highlights of the year, key figures and a link to download the full Annual Report. It does not contain the full set of financial statements or notes that you would expect in the actual Annual Report (10‐K), rather it announces that the report has been approved and published and points users to the attachments. This matches the definition of a Report Publication Announcement (RPA).
2026-03-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.